JP2022506156A5 - - Google Patents

Info

Publication number
JP2022506156A5
JP2022506156A5 JP2021523353A JP2021523353A JP2022506156A5 JP 2022506156 A5 JP2022506156 A5 JP 2022506156A5 JP 2021523353 A JP2021523353 A JP 2021523353A JP 2021523353 A JP2021523353 A JP 2021523353A JP 2022506156 A5 JP2022506156 A5 JP 2022506156A5
Authority
JP
Japan
Prior art keywords
promoter
translation unit
host cell
cell chromosome
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523353A
Other languages
English (en)
Japanese (ja)
Other versions
JP7620546B2 (ja
JP2022506156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059661 external-priority patent/WO2020096959A1/en
Publication of JP2022506156A publication Critical patent/JP2022506156A/ja
Publication of JP2022506156A5 publication Critical patent/JP2022506156A5/ja
Priority to JP2024132069A priority Critical patent/JP2024170419A/ja
Application granted granted Critical
Publication of JP7620546B2 publication Critical patent/JP7620546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523353A 2018-11-05 2019-11-04 原核宿主細胞における2鎖タンパク質の産生方法 Active JP7620546B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024132069A JP2024170419A (ja) 2018-11-05 2024-08-08 原核宿主細胞における2鎖タンパク質の産生方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755915P 2018-11-05 2018-11-05
US62/755,915 2018-11-05
PCT/US2019/059661 WO2020096959A1 (en) 2018-11-05 2019-11-04 Methods of producing two chain proteins in prokaryotic host cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024132069A Division JP2024170419A (ja) 2018-11-05 2024-08-08 原核宿主細胞における2鎖タンパク質の産生方法

Publications (3)

Publication Number Publication Date
JP2022506156A JP2022506156A (ja) 2022-01-17
JP2022506156A5 true JP2022506156A5 (https=) 2022-11-11
JP7620546B2 JP7620546B2 (ja) 2025-01-23

Family

ID=69165497

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523353A Active JP7620546B2 (ja) 2018-11-05 2019-11-04 原核宿主細胞における2鎖タンパク質の産生方法
JP2024132069A Withdrawn JP2024170419A (ja) 2018-11-05 2024-08-08 原核宿主細胞における2鎖タンパク質の産生方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024132069A Withdrawn JP2024170419A (ja) 2018-11-05 2024-08-08 原核宿主細胞における2鎖タンパク質の産生方法

Country Status (11)

Country Link
US (2) US12291712B2 (https=)
EP (1) EP3877407B1 (https=)
JP (2) JP7620546B2 (https=)
KR (1) KR20210090645A (https=)
CN (1) CN113260626B (https=)
AU (1) AU2019375413A1 (https=)
CA (1) CA3117051A1 (https=)
IL (1) IL282800A (https=)
SG (1) SG11202104104VA (https=)
TW (1) TWI872030B (https=)
WO (1) WO2020096959A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230044394A (ko) * 2020-06-09 2023-04-04 아이코사백스, 인크. 바이러스 유사 입자를 제조하는 방법

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2034021A1 (en) 1996-08-23 2009-03-11 Peter Ruhdal Jensen Artificial promoter libraries for selected organisms and promoters derived from such libraries
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
JP2000083670A (ja) 1998-09-09 2000-03-28 Hsp Kenkyusho:Kk DsbA/DsbB/DsbC/DsbD発現プラスミド
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
WO2002061090A2 (en) 2000-12-14 2002-08-08 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
CN100513414C (zh) * 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物
US10000574B2 (en) 2003-11-28 2018-06-19 Amgen Research (Munich) Gmbh Compositions comprising polypeptides
CN100537771C (zh) * 2003-12-04 2009-09-09 北京安波特基因工程技术有限公司 一种大肠杆菌周质腔分泌型表达载体
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
WO2008142028A1 (en) 2007-05-17 2008-11-27 Boehringer Ingelheim Rcv Gmbh & Co Kg Method for producing a recombinant protein on a manufacturing scale
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US20110136169A1 (en) * 2009-11-20 2011-06-09 Rutgers, The State University Of New Jersey Expression system compositions and methods
GB201000588D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
HRP20180226T1 (hr) * 2011-07-13 2018-03-09 Ucb Biopharma Sprl Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
US20150353940A1 (en) 2013-08-05 2015-12-10 Absci, Llc Vectors for use in an inducible coexpression system
WO2017106583A1 (en) * 2015-12-15 2017-06-22 Absci, Llc Cytoplasmic expression system
SG11201508642WA (en) 2013-04-19 2015-11-27 Sutro Biopharma Inc Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
WO2016073791A1 (en) * 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
US10066002B2 (en) * 2014-11-05 2018-09-04 Genentech, Inc. Methods of producing two chain proteins in bacteria
CR20170240A (es) 2014-11-10 2018-04-03 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos

Similar Documents

Publication Publication Date Title
JP2017533730A5 (https=)
Baneyx et al. Recombinant protein folding and misfolding in Escherichia coli
De Marco Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli
Choi et al. Secretory and extracellular production of recombinant proteins using Escherichia coli
Kolaj et al. Use of folding modulators to improve heterologous protein production in Escherichia coli
Khushoo et al. Optimization of extracellular production of recombinant asparaginase in Escherichia coli in shake-flask and bioreactor
JP2016518833A5 (https=)
US11365418B2 (en) Dual cistronic bacterial expression system
CL2008002349A1 (es) Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.
Samuelson Recent developments in difficult protein expression: a guide to E. coli strains, promoters, and relevant host mutations
RU2017119396A (ru) Способы получения двуцепочечных белков в бактериях
JP2018500008A5 (https=)
Tanimura et al. Improvement of ectoine productivity by using sugar transporter-overexpressing Halomonas elongata
Ata et al. Codon optimization of xylA gene for recombinant glucose isomerase production in Pichia pastoris and fed-batch feeding strategies to fine-tune bioreactor performance
Lian et al. Improving aquaporin Z expression in Escherichia coli by fusion partners and subsequent condition optimization
JP2022506156A5 (https=)
Behravan et al. RSM-based model to predict optimum fermentation conditions for soluble expression of the antibody fragment derived from 4D5MOC-B humanized mab in SHuffle™ T7 E. coli
Dariushnejad et al. Effect of DnaK/DnaJ/GrpE and DsbC chaperons on periplasmic expression of Fab antibody by E. coli SEC pathway
RU2017119403A (ru) Способы получения двуцепочечных белков в бактериях
Lénon et al. Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
Sun et al. Co-expression of Dsb proteins enables soluble expression of a single-chain variable fragment (scFv) against human type 1 insulin-like growth factor receptor (IGF-1R) in E. coli
Zhong et al. Tandem repeat mhBD2 gene enhance the soluble fusion expression of hBD2 in Escherichia coli
US20180057823A1 (en) Expression Vector
Kim et al. Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains
CN103797122A (zh) 用于大肠杆菌中异源蛋白质生产的新的表达和分泌载体系统